BaCkground: There have been no studies to date on the frequency and reactivity of aanti-melanoma differentiation--associated gene 5 (anti-MDA-5) in samples from the Brazilian population with dermatomyositis. oBjeCtives. To analyze this autoantibody in the Brazilian population. Methods: This was a single-center cross-sectional study in which 131 consecutive adult patients (109 dermatomyositis and 22 clinically amyopathic dermatomyositis) with active disease were evaluated from 2000 to 2016. Analysis of the anti-MDA-5 autoantibody was performed by ELISA. results: The presence of this autoantibody was observed in 14.7% and 22.7% of patients with dermatomyositis and clinically amyopathic dermatomyositis, respectively. In the case of dermatomyositis, the autoantibody was associated less frequently with Raynaud's phenomenon and periungual hyperemia (P<0.05). In clinically amyopathic dermatomyositis, the presence of this autoantibody was not associated statistically with any demographic, clinical, laboratory, or imaging characteristics. study liMitations: The cross-sectional study design did not allow establishing a temporal correlation between anti-MDA-5 autoantibody and various study variables. In addition, pulmonary function tests were not performed in the patients. ConClusions. The frequency of anti-MDA-5 autoantibody was comparable to that of other populations with dermatomyositis, but with a different reactivity than described in the literature. In addition, there was a phenotypic variability between our patients with clinically amyopathic dermatomyositis and those described in the literature. Further studies are needed to confirm the current study's findings and elucidate this autoantibody's reactivity in Brazilians with idiopathic inflammatory myopathies. and suspected cases of muscular dystrophies.
INTRODUCTION
Dermatomyositis (DM) is an autoimmune inflammatory myopathy characterized by muscle weakness of the limbs, mainly proximal, symmetric, and progressive, in addition to classic cutaneous alterations such as heliotrope rash and Gottron's papules. It can also present other skin lesions such as cuticular hypertrophy, periungual hyperemia, photosensitivity, calcinosis, "V-neck sign", and "shawl sign", among others. [1] [2] [3] In 10-15% of cases, DM patients do not present muscle involvement, thus characterizing the DM subset known as amyopathic or sine myositis. 4, 5 DM can also be classified as hypomyopathic, with altered laboratory results, evidencing some degree of myopathy. These two forms of DM (amyopathic and hypomyopathic) are called clinically amyopathic DM. 2, 5 Sato et al. 6 identified the autoantibody to the 140-kDa clinically amyopathic dermatomyositis peptide in Japanese patients with clinically amyopathic DM and whose principal characteristic was rapidly progressive pulmonary involvement. The target antigen for this autoantibody is the 140-kDa cytoplasmic protein called melanoma differentiation associated gene 5 (MDA-5), an RNA-specific helicase. 7 Therefore, anti-CADM-140 is now also referred to as anti-MDA-5. (rash, palmar papules, and/or ulcerations), joint and lung involvement, and/or worse prognosis in DM patients. [7] [8] [9] [10] [11] [12] [13] Some of these patients also presented a similar phenotype to that of anti-synthetase syndrome. 14 However, this wide phenotypical variability between the studies on the association with anti-MDA-5 autoantibody may be due to the heterogeneity of the populations studied, thus justifying the importance of assessing Brazilian patients with idiopathic inflammatory myopathies.
These studies also failed to mention possible confounders (smoking, chronic obstructive pulmonary disease, and overlapping of other systemic autoimmune diseases such as systemic sclerosis, systemic lupus erythematosus, and Sjögren's syndrome, among others), which could interfere in the correlation between anti-MDA-5 autoantibody and the patients' clinical and laboratory parameters. 8, [10] [11] [12] [13] [14] [15] [16] Presence of anti-MDA-5 autoantibody had not been analyzed previously in Brazilian patients with DM, thus justifying the current study, with the aim of verifying the autoantibody's prevalence in patients with DM and clinically amyopathic DM, without possible confounders. The study also aimed to assess a possible association between the autoantibody and demographic, clinical, laboratory, and imaging parameters.
METHODS
This was a single-center cross-sectional study to evaluate the presence of anti-MDA-5 autoantibody in adult patients with DM, defined according to the criteria proposed by Bohan and Peter. 1 Clinically amyopathic DM was determined according to the criteria of Gerami et al. 16 All the assessed patients came from the same tertiary service, from 2000 to 2016. 
Statistical analysis
The Kolmogorov-Smirnov test was used to assess the distribu- Statistical significance was set at p<0.05. Constitutional symptoms were present in more than half of the cases in both groups ( Table 1 ).
RESULTS

Of
The principal cutaneous manifestations were heliotrope rash and Gottron's sign/papules, followed by secondary lesions (facial rash, "V-neck" sign, "shawl" sign, periungual hyperemia, vasculitis, calcinosis, mechanic's hand, ulcers, and Raynaud's phenomenon).
As expected, muscle weakness in the limbs and elevated serum muscle enzymes were more evident in the classic form of DM, compared to clinically amyopathic DM.
Joint involvement and dysphagia were also found in both groups. In patients with clinically amyopathic DM, all the demographic, clinical, laboratory, and imaging parameters were similar in those with MDA-5(+) and MDA-5(-) ( Table 3 ).
An Bras Dermatol. 2018;93 (4):517-23. Although this was a retrospective study, the data had been previously standardized and parameterized and were thus trustworthy. In addition, in order to increase the specificity of the ELISA test, we applied a cutoff point of at least three standard deviations to include cases in the study, unlike previous studies such as Labrador-Horrillo et al., 14 who used two standard deviations as their cutoff.
According to the literature, positivity for anti-MDA-5 autoantibody can vary from 4.7 to 13.1% in DM and 10.0 to 18.8% in patients with clinically amyopathic DM. 7, [11] [12] [13] [14] In the current study, MDA-5 autoantibody was present in 14.7% of patients with DM and 22.7% in clinically amyopathic DM, thus corroborating the rates reported in the literature. Since anti-MDA-5 autoantibody can vary according to disease activity, it is important to note that the current study only included patients with clinical and laboratory activity. [18] [19] [20] In patients with classic DM, anti-MDA-5 autoantibody was associated with lower frequency of Raynaud's phenomenon and periungual hyperemia. However, unlike other studies, we did not find an association between this autoantibody and the presence of skin ulcers, for example. [12] [13] [14] Further studies are needed to better elucidate the relevance of these associations.
Neither did we observe an association between anti-MDA-5 autoantibody and a clinical presentation similar to anti-synthetase syndrome or its components (e.g., joint and pulmonary involvement). However, Hall et al. 12 and Labrador-Horrillo et al. 14 reported a high rate of anti-MDA-5 autoantibody in patients with symptoms suggestive of anti-synthetase syndrome, but without the presence of anti-synthetase autoantibody (e.g., anti-Jo-1 autoantibody). These discrepant data reinforce the presence of wide phenotypical variability among the different populations studied, as well as different anti-MDA-5 autoantibody reactivity according to the study population.
Unlike our study, those authors did not mention possible confounding factors that could lead to lung or joint involvement in their series (e.g., overlapping diagnoses, history of smoking, chronic obstructive pulmonary disease (COPD), history of tuberculosis, etc.). 12, 14 In patients with clinically amyopathic DM we observed a variety of skin lesions, mainly Gottron's sign/papules, heliotrope rash, facial rash, and periungual hyperemia. These were distributed the same way in patients with or without presence of anti-MDA-5 autoantibody. In contrast, studies in the literature reported a strong association between this autoantibody and the skin lesions found in patients with clinically amyopathic DM. 6, 8, [12] [13] [14] Pulmonary involvement in patients with clinically amyopathic DM is relatively common. 6, [20] [21] [22] [23] [24] Particularly in Japanese and Chinese populations, it has been reported frequently in patients with rapidly progressive interstitial lung disease. 6, [20] [21] [22] [23] [24] Meanwhile, the prevalence of rapidly progressive interstitial lung disease in clinically amyopathic DM is relatively low in the United States, as in the current study. 25 Previous studies also showed a strong association between anti-MDA-5 autoantibody and presence of pulmonary manifestations, which we did not observe in this study. 6, 9, 14 One explanation is that we found a low rate of patients with pulmonary involvement and rapidly progressive dyspnea. These findings in turn may be the consequence of phenotypical diversity in the study sample, as well as the use of strict exclusion criteria, especially for factors related to pulmonary involvement (COPD, smoking, etc.).
As limitations, the study used a cross-sectional design, which prevented establishing a temporal correlation between anti-MDA-5 autoantibody and various independent variables. In addition, lung function tests were not performed in the patients. 
